Teacher Retirement System of Texas Acquires 2,544 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Teacher Retirement System of Texas boosted its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 18.5% during the 4th quarter, HoldingsChannel.com reports. The firm owned 16,331 shares of the specialty pharmaceutical company’s stock after purchasing an additional 2,544 shares during the period. Teacher Retirement System of Texas’ holdings in Supernus Pharmaceuticals were worth $591,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the business. Geode Capital Management LLC raised its stake in Supernus Pharmaceuticals by 5.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,482,051 shares of the specialty pharmaceutical company’s stock valued at $46,218,000 after buying an additional 74,438 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of Supernus Pharmaceuticals by 5.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 753,363 shares of the specialty pharmaceutical company’s stock worth $27,242,000 after acquiring an additional 40,968 shares during the period. Bank of New York Mellon Corp grew its holdings in Supernus Pharmaceuticals by 7.3% during the 4th quarter. Bank of New York Mellon Corp now owns 399,584 shares of the specialty pharmaceutical company’s stock valued at $14,449,000 after buying an additional 27,134 shares in the last quarter. Principal Financial Group Inc. boosted its stake in Supernus Pharmaceuticals by 4.0% during the fourth quarter. Principal Financial Group Inc. now owns 296,732 shares of the specialty pharmaceutical company’s stock valued at $10,730,000 after buying an additional 11,321 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its position in shares of Supernus Pharmaceuticals by 40.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 253,396 shares of the specialty pharmaceutical company’s stock valued at $7,901,000 after acquiring an additional 73,118 shares during the last quarter.

Analysts Set New Price Targets

Several brokerages have weighed in on SUPN. StockNews.com cut Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, March 24th. Cantor Fitzgerald reissued a “neutral” rating and set a $36.00 target price on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th.

Insider Transactions at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 9,477 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $39.70, for a total transaction of $376,236.90. Following the completion of the sale, the vice president now directly owns 10,149 shares in the company, valued at approximately $402,915.30. The trade was a 48.29 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Jonathan Rubin sold 927 shares of the company’s stock in a transaction on Friday, February 21st. The shares were sold at an average price of $39.15, for a total transaction of $36,292.05. Following the completion of the sale, the senior vice president now directly owns 7,853 shares in the company, valued at approximately $307,444.95. The trade was a 10.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 11,104 shares of company stock worth $440,263. Company insiders own 9.30% of the company’s stock.

Supernus Pharmaceuticals Stock Performance

Shares of NASDAQ SUPN opened at $32.29 on Monday. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $25.53 and a fifty-two week high of $40.28. The company has a market cap of $1.80 billion, a PE ratio of 30.18 and a beta of 0.83. The business has a 50-day simple moving average of $35.15 and a two-hundred day simple moving average of $35.04.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.